Posted by Michael Wonder on 11 Oct 2016
NICE publishes draft guidance on the use of Otezla on the NHS
11 October 2016 - NICE has published draft guidance on the use of Otelza (apremilast) on the NHS by patients with active psoriatic arthritis.
Apremilast, used alone or in combination with a disease-modifying anti-rheumatic drug (DMARD), is recommended within its marketing authorisation as an option for treating active psoriatic arthritis in adults, when:
- their disease has not responded to DMARDs or
- DMARDs are not tolerated and
- the company provides apremilast with the discount agreed in the patient access scheme
